

The regulatory effect of blood group on ferritin levels in aging: a retrospective study

Ni Xiaolin¹, Fenghong Yao² and Mingkang Pan²

¹ State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

² Beijing Zhongguancun Hospital, Beijing, China

ABSTRACT

Background. Ferritin plays a pivotal role in the ageing process. Previous studies have identified statistically significant differences in ferritin levels among various ABO blood groups. However, the interaction between the ABO blood group and ferritin levels during senescence remains underexplored.

Methods. This research was conducted as a retrospective study involving a cohort of 3,843 individuals aged 40 and over who underwent blood type and ferritin testing at Beijing Zhongguancun Hospital. Assumption testing is employed to assess the normal distribution of continuous variables in the context of regression analysis. Spearman correlation analysis was employed to examine the relationship between the non-normally distributed biochemical indicators and ferritin levels. Age was considered the independent variable, while gender and biochemical indicators related to ferritin served as control variables. Blood type was analyzed as a moderating factor to evaluate its impact on the relationship between age and ferritin levels.

Results. Our findings revealed a negative correlation between ferritin and age ($\rho = -0.099$, $p < 0.001$). Significant differences in ferritin levels were observed between genders ($p = 0.005$) and blood groups ($p < 0.001$). The influence of age on ferritin levels varied across different blood groups, particularly in individuals with blood types A ($p = 0.003$, $\beta = -0.072$) and B ($p < 0.001$, $\beta = -0.110$), where the negative association between age and ferritin was more pronounced.

Conclusion. ABO blood type may influence ferritin levels as individuals age. Notably, in individuals with blood types A and B, the inverse relationship between age and ferritin levels was particularly significant among middle-aged and elderly individuals. These findings suggested the potential benefit of targeted iron supplementation for this population.

Submitted 23 October 2024

Accepted 17 March 2025

Published 14 April 2025

Corresponding authors

Ni Xiaolin, xiaolin_ni7@126.com

Mingkang Pan, panmkang@163.com

Academic editor

Faizan Kashoo

Additional Information and Declarations can be found on page 11

DOI 10.7717/peerj.19281

© Copyright

2025 Xiaolin et al.

Distributed under

Creative Commons CC-BY 4.0

OPEN ACCESS

Subjects Epidemiology, Geriatrics, Public Health

Keywords Ferritin levels, ABO blood group, Aging, Regulatory effect, Retrospective study

INTRODUCTION

Rapid population ageing has emerged as a significant public health challenge in China and globally, as the deterioration of tissues and organs associated with ageing is a primary contributor to many chronic diseases (Liu et al., 2018). This degeneration will be reflected in the fluctuations of physiological indicators, which indirectly reflect the state of health

([Dieteren et al., 2020](#)). As a result, it is imperative to implement preventive strategies and interventions that focus on critical physiological indicators conducive to healthy ageing.

Among the various physiological indicators, ferritin, which serves as a principal iron storage protein, is integral to numerous physiological and pathological processes. These include coronary artery disease, malignancies, sideroblastic anemias, neurodegenerative disorders, and hemophagocytic syndrome ([Li et al., 2024](#)). It has been proposed that serum ferritin (SF) can transport iron into cells, constituting the main pathway of iron supply to oligodendrocytes for myelin production, and then involved in neurotransmitter synthesis in the central nervous system, thus affecting working memory ([Rosell-Díaz et al., 2023](#)). In later life, reduced iron stores are associated with an increased risk of impaired physical and cognitive capacity, as well as up to a twofold higher risk of mortality ([Rosell-Díaz et al., 2023](#); [Philip et al., 2020](#)). A cross-sectional study of the Ageing Health cohort (aged 65–90 years) found that SF positively correlates with neocortical amyloid- β load (NAL), suggesting that ferritin has the potential to serve as a blood biomarker panel for preclinical Alzheimer's disease (AD) ([Goozee et al., 2018](#)). In addition, iron plays a crucial role in erythropoiesis, oxygen transport throughout the circulatory system, mitochondrial respiration, and protection against free radicals in high-energy-demand cells, such as cardiomyocytes ([Hoes et al., 2018](#)). Research has demonstrated that serum ferritin levels decline with age, while the prevalence of heart failure (HF) rises ([Aboelsaad et al., 2024](#)). Therefore, understanding the characteristics of iron levels with age may have significant clinical implications, especially considering the availability of routine blood tests to detect iron deficiency and various therapeutic options for iron repletion.

Recently, an intriguing study revealed that statistically significant variations in ferritin levels across different ABO blood groups ($p < 0.001$) among a total of 7,723 healthy blood donors. Specifically, individuals with blood type A exhibited lower concentrations of ferritin, whereas those with blood type B displayed markedly elevated ferritin levels ([Franchini et al., 2016](#)). The relationship between serum ferritin levels and the incidence of COVID-19 is also influenced by ABO blood groups ([Lawaczeck, 2020](#)). As we know, ABO blood groups are ABO antigens (*i.e.*, A, B, AB, and O), which are glycoproteins and glycolipids expressed by the ABO gene on the surface of red blood cells, as well as a variety of human cells and tissues ([Anani et al., 2020](#)). Therefore, the clinical significance of ABO blood type extends beyond transfusion medicine and solid organ or hematopoietic transplantation. These antigens may also participate in the pathogenesis of various systemic diseases, including cancer, diabetes, infectious disorders, and cardiovascular disease ([Abegaz, 2021](#)). Therefore, the vast majority of studies have limited their investigation of this intriguing relationship to cohorts of high-risk patients, resulting in a scarcity of evidence regarding the physiological influence of ABO antigens on baseline levels of hematological and metabolic parameters. Given the changes in iron levels with age and the potential impact of blood type on these levels, it remains unclear whether blood type exerts a regulatory effect on iron levels in healthy ageing populations ([Fig. 1](#)). We propose that there exists an interaction between ABO blood group and ferritin levels throughout the aging process. To explore this ambiguous association, we conducted a study within the Beijing Health Examination Cohort (BHEC) to examine the influence of different blood




Figure 1 Schematic diagram of this study design.

Full-size DOI: 10.7717/peerj.19281/fig-1

types on ferritin levels in ageing individuals, with the aim of guiding personalized clinical treatment in the future.

MATERIALS & METHODS

Study design and participants

The biochemical examination data were collected from 3,843 individuals aged 40 and above who underwent blood type and ferritin testing at Beijing Zhongguancun Hospital between July 2019 and July 2024. A total of 883 middle-aged and elderly individuals with missing a large number of examination data were excluded from the study. Ultimately, 2,960 healthy participants were included in this retrospective study. The Ethics Committee of the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, approved the study protocol (ZS2024001). The study was conducted in accordance with the Declaration of Helsinki and its amendments. All participants provided written informed consent prior to enrollment. Clinical trial number: not applicable.

Measures

Age, sex, self-reported health status, and medical history were recorded. Blood samples were obtained under fasting conditions and analyzed within 2 h of centrifugation. The blood chemistry studied was assessed by standard automated techniques, including Architect C 8000 auto-analyzer and AxSyme Third-Generation Immunoassay System (Abbott, Abbott Park, IL, USA). This analysis included indicators of liver function, glycometabolism, lipid metabolism, myocardial function, thyroid function, and inflammatory factors (Table S1).

Statistical analysis

Descriptive statistics and Spearman correlation analysis were conducted using SPSS version 27.0 (SPSS Inc., Armonk, NY, USA). Continuous variables are presented as mean \pm standard deviation, while categorical variables are presented as frequency (percentage). Then, assumption testing is employed to assess the normal distribution of continuous variables in the context of regression analysis. The normal distribution of continuous variables was assessed using the Kolmogorov–Smirnov and Shapiro–Wilk tests. The Mann–Whitney test was employed to compare the normal distribution between the two gender groups. The Kruskal–Wallis test was utilized to compare median differences among multiple blood type groups. *P*-values less than 0.05 in assumption testing were considered not consistent with the normal distribution. Spearman correlation analysis was performed to evaluate the relationship between biochemical indices and ferritin levels. Finally, age was treated as the independent variable, with gender and biochemical indicators associated with ferritin serving as control variables. Blood type was analyzed as a moderating variable to determine its effect on the relationship between age and ferritin levels. *P*-values less than 0.05 were considered statistically significant.

RESULTS

Descriptive statistical analysis of each biochemical index

We collected biochemical examination data from 3,843 individuals aged 40 and above who underwent health check-ups at Beijing Zhongguancun Hospital. A total of 2,960 healthy participants, with an average age of 53.96 ± 12.19 years, were included in this study, of which 900 (30.41%) were male. Among these participants, 859 (29.02%) had blood type O, 831 (28.07%) had type A, 978 (33.04%) had type B, and 292 (9.86%) had type AB (Table 1). There were individual differences in various biochemical indices, particularly in liver and kidney function, metabolic function, and myocardial damage. Notably, the mean ferritin level was 288.16, with a standard deviation of 99.89, indicating significant variability in ferritin levels among individuals. However, the median values of all indicators were close to the mean (Table 1), suggesting that the distribution of these indicators is relatively concentrated and suitable for further correlation and regression analyses. The flowchart of this study was shown in Fig. 2.

Table 1 The characteristics of all variables.

Variable	N	Mean/(n, %)	Standard deviation	Median
Age	2,960	53.959	12.185	51.000
Gender	2,960	Male (n = 900, 30.41%) Female (n = 2060, 69.59%)		
Blood group	2,960	A (n = 831, 28.07%) B (n = 978, 33.04%) O (n = 859, 29.02%) AB (n = 292, 9.86%)		
Fer	2,960	288.162	99.894	303.210
ALT	2,960	22.262	16.081	19.000
AST	2,960	22.375	13.315	20.300
ALP	2,960	73.943	25.553	82.510
Cr	2,960	68.404	22.250	65.000
GGT	2,960	30.733	28.747	22.000
GLOB	2,960	26.969	3.153	27.010
A/G	2,960	1.575	0.195	1.550
Glu	2,960	5.321	0.732	5.290
sd LDL-C	2,960	0.848	0.284	0.849
LDL-C	2,960	2.892	0.410	2.900
HDL-C	2,960	1.233	0.166	1.230
Lpa	2,960	205.518	117.043	224.090
APOA1	2,960	1.319	0.194	1.290
LDH	2,960	234.456	41.973	253.960
LDH-1	2,960	40.484	6.914	43.590
CK	2,960	112.398	38.566	119.700
CK-MB	2,960	15.736	4.454	17.560
α -HBDH	2,960	168.106	25.968	178.310
NT-pro BNP	2,960	1,157.057	532.537	1,316.280
TnT	2,960	0.045	0.031	0.050
Mb	2,960	91.523	57.111	100.490
TSH	2,960	2.647	0.753	2.750
FT3	2,960	4.301	0.385	4.240
T3	2,960	1.510	0.158	1.490
FT4	2,960	15.849	1.101	15.860
IL-6	2,960	76.228	20.823	81.630

Notes.

N/n, number; Fer, ferritin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cr, creatinine; GGT, gamma-glutamyltranspeptidase; ALP, alkaline phosphatase; GLOB, globulin; A/G, albumin/hglobulin; Glu, glucose; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; sd LDL-C, small and dense low density cholesterol; Lpa, lipoprotein a; APOA1, apolipoprotein A1; LDH, lactate dehydrogenase; LDH-1, lactate dehydrogenase isoenzyme; CK, creatine kinase; CK-MB, creatine kinase-MB isoenzyme activity; α -HBDH, alpha hydroxybutyrate dehydrogenase; NT-pro BNP, N-terminal -B type natriuretic peptide precursor; TnT, troponin T; Mb, Myohemoglobin; TSH, thyroid stimulating hormone; FT3, free triiodothyronine; T3, triiodothyronine; FT4, free thyroxine; IL-6, interleukin-6.




Figure 2 The flowchart of this study.

Full-size DOI: 10.7717/peerj.19281/fig-2

Correlation and univariate analysis of ferritin and other indicators

Since all variables did not conform to a normal distribution ($p < 0.05$) (Table S2). Spearman correlation analysis was employed for continuous variables, while a non-parametric test was utilized for categorical variables.

The results indicated a negative correlation between ferritin levels and age ($\rho = -0.099$, $p < 0.001$), suggesting that ferritin levels tend to decrease as age increases (Table 2). Additionally, the difference in ferritin levels between men and women was statistically significant ($p = 0.005$) (Table 3), highlighting a notable disparity in ferritin levels between the sexes. Furthermore, there were statistically significant differences in ferritin levels across various blood groups ($p < 0.001$) (Table 4).

Alanine aminotransferase (ALT) ($\rho = 0.078$, $p < 0.001$), aspartate aminotransferase (AST) ($\rho = 0.039$, $p < 0.05$), γ -glutamyl transpeptidase (γ -GT) ($\rho = 0.074$, $p < 0.001$), creatinine (Cr) ($\rho = 0.105$, $p < 0.001$), alkaline phosphatase (ALP) ($\rho = 0.113$, $p < 0.001$), and lipoprotein(a) (LP(a)) ($\rho = 0.059$, $p < 0.01$) demonstrated significant positive correlations with ferritin (Table 2). This suggests that abnormalities in liver, bile, and renal function are associated with increased ferritin levels.

Table 2 Spearman correlation analysis between continuous variables and ferritin.

Variables	Correlation coefficient
Age	-0.099***
ALT	0.078***
AST	0.039*
ALP	0.113***
Cr	0.105***
GGT	0.074***
GLOB	0.026
A/G	-0.035
Glu	0.042*
LDL-C	0.017
HDL-C	-0.067***
sd LDL-C	0.038*
Lpa	0.059**
APOA1	-0.086***
LDH	0.224***
LDH-1	0.221***
CK	0.156***
CK-MB	0.210***
α -HBDH	0.195***
NT-pro BNP	0.189***
TnT	0.209***
Mb	0.207***
TSH	0.126***
FT3	-0.174***
T3	-0.168***
FT4	0.027
IL-6	0.103***

Notes.**p*-value < 0.05.***p*-value < 0.01.****p*-value < 0.001.

Fer, ferritin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cr, creatinine; GGT, gamma-glutamyltranspeptidase; ALP, alkaline phosphatase; GLOB, globulin; A/G, albumin/hglobulin; Glu, glucose; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; sd LDL-C, small and dense low density cholesterol; Lpa, lipoprotein a; APOA1, apolipoprotein A1; LDH, lactate dehydrogenase; LDH-1, lactate dehydrogenase isoenzyme; CK, creatine kinase; CK-MB, creatine kinase-MB isoenzyme activity; α -HBDH, alpha hydroxybutyrate dehydrogenase; NT-pro BNP, N-terminal -B type natriuretic peptide precursor; TnT, troponin T; Mb, Myohemoglobin; TSH, thyroid stimulating hormone; FT3, free triiodothyronine; T3, triiodothyronine; FT4, free thyroxine; IL-6, interleukin-6.

There was a significant negative correlation between apolipoprotein A1 (APOA1) and ferritin ($\rho = -0.086$, $p < 0.001$) (Table 2), suggesting that an increase in ferritin levels is associated with a decrease in high-density lipoprotein (HDL) metabolism.

There were significant positive correlations between ferritin and creatine kinase (CK) ($\rho = 0.156$, $p < 0.001$), lactate dehydrogenase (LDH) ($\rho = 0.224$, $p < 0.001$), and myoglobin (Mb) ($\rho = 0.207$, $p < 0.001$) (Table 2). These findings suggested that elevated ferritin levels may be closely associated with myocardial injury.

Table 3 Univariate analysis of categorical variables (gender).

Gender	Median (P25, P75)		Mann–Whitney test Statistic U value	Mann–Whitney test Statistic z value	p-value
	Male (n = 900)	Female (n = 2060)			
Fer	301.520 (300.4, 303.6)	302.210 (301.3, 305.4)	869,207.500	-2.786	0.005

Table 4 Univariate analysis of categorical variables (blood group).

Blood type	Median (P25, P75)				Kruskal–Wallis test Statistic H value	p-value
	O (n = 859)	A (n = 831)	B (n = 978)	AB (n = 292)		
Fer	303.050 (302.5, 303.8)	303.080 (302.5, 303.7)	305.070 (3,042.5, 305.7)	306.040 (306.4, 307.6)	24.780	<0.001

Thyroid-stimulating hormone (TSH) ($\rho = 0.126$, $p < 0.001$) exhibited a positive correlation with ferritin, whereas free triiodothyronine (FT3) ($\rho = -0.174$, $p < 0.001$) and total triiodothyronine (TT3) ($\rho = -0.168$, $p < 0.001$) demonstrated negative correlations with ferritin (Table 2). These findings suggested a relationship between thyroid function and ferritin levels.

Interleukin-6 (IL-6) ($\rho = 0.103$, $p < 0.001$) exhibited a positive correlation with ferritin (Table 2), suggesting that ferritin levels are closely associated with the elevation of inflammatory factors.

Glucose (Glu) ($\rho = 0.042$, $p < 0.05$) and small and dense low-density lipoprotein cholesterol (sd LDL-C) ($\rho = 0.038$, $p < 0.05$) exhibited a weak positive correlation with ferritin (Table 2). This finding suggested that metabolic disorders may be associated with ferritin levels.

The regulatory effect of blood group on ferritin levels with aging

We included indicators related to ferritin and analyzed the regulatory effects with age as the independent variable, gender and other biochemical indicators as control variables, and blood type as the moderating variable.

In Model 1, which analyzed the direct effects of age and several control variables (including gender, ALT, AST, creatinine, glucose, etc.) on ferritin levels, age exhibited a significant negative effect on ferritin levels ($t = -2.340$, $p = 0.019$). Specifically, as age increased, ferritin levels decreased significantly (Table 5). These results indicate that age is an independent factor influencing ferritin levels.

Model 2 incorporates blood type as a regulatory variable based on Model 1 to investigate whether different blood types influence the relationship between age and ferritin levels. The results indicated that blood group B ($p = 0.042$) and blood group AB ($p = 0.048$) had significant effects on ferritin levels compared to blood group O, while blood group A did not show a significant difference (Table 5). This suggests that blood groups B and AB may modulate the effect of age on ferritin levels to some extent.

Table 5 The regulatory effect of blood group on the level of ferritin with aging.

	Model 1					Model 2					Model 3				
	B	Standard error	t	p-value	β	B	Standard error	t	p-value	β	B	Standard error	t	p-value	β
Age	-0.384	0.164	-2.34	0.019	-0.047	-0.389	0.164	-2.375	0.018	-0.048	-0.437	0.218	-2.004	0.048	-0.045
Blood type O	-														
Blood type A						-4.872	4.652	-1.047	0.295	-0.022	-4.758	4.640	-1.026	0.305	-0.021
Blood type B						-9.069	4.467	-2.03	0.042	-0.043	-9.058	4.455	-2.033	0.042	-0.043
Blood type AB						-12.768	6.462	-1.976	0.048	-0.038	-12.65	6.444	-1.963	0.050	-0.038
Age*Blood type A										-1.143	0.388		-2.943	0.003	-0.072
Age*Blood type B										-1.552	0.365		-4.248	p < 0.001	-0.110
Age*Blood type AB										-1.102	0.517		-2.132	0.033	-0.044
Constant	467.502	34.066	13.724	p < 0.001	-	471.505	34.107	13.824	p < 0.001	-	466.88	34.065	13.706	p < 0.001	-
Control variable			Yes					Yes					Yes		
R ²			0.101					0.103					0.109		
Adjust R ²			0.094					0.095					0.100		
F value	F (24, 2935) = 13.781, p < 0.001					F (27, 2932) = 12.482, p < 0.001					F (30, 2929) = 11.929, p < 0.001				

Model 3 further incorporated the interaction term of age and blood type to elucidate the specific regulatory effects of different blood types on the relationship between age and ferritin levels. The results indicated that various blood groups indeed play a significant regulatory role in this relationship. In blood group A ($p = 0.003$, $\beta = -0.072$) and blood group B ($p < 0.001$, $\beta = -0.110$), the negative impact of age on ferritin levels was more pronounced, demonstrating a stronger regulatory effect compared to other blood groups. In populations with blood group AB ($p = 0.033$, $\beta = -0.044$), the negative effect of age on ferritin was greater than that observed in blood group O, although the regulatory effect was relatively weak (Table 5).

DISCUSSION

Ferritin is a vital protein complex responsible for storing excess cellular iron and plays a crucial role in various metabolic pathways, inflammatory processes, stress responses, and the pathogenesis of cancer and neurodegenerative diseases (Fang *et al.*, 2020; Sudarev *et al.*, 2023). In recent years, ferritin has been shown to play a central role in senescence, driving the senescence-associated secretory phenotype (SASP) through the induction of senescence and iron accumulation in senescent cells (Maus *et al.*, 2023). A cohort study found that both low and high serum ferritin levels were associated with an increased risk of incident heart failure in the general population (Silvestre *et al.*, 2017). A meta-analysis of 11 studies revealed that serum ferritin levels were higher in patients with non-alcoholic fatty liver disease (NAFLD) compared to healthy individuals and were associated with the risk of developing NAFLD (Yan *et al.*, 2023). A longitudinal study involving 6,497 participants found that serum ferritin levels were positively and independently associated with the incidence of type 2 diabetes (T2D) and cerebrovascular disease (CEVD) (Suárez-Ortegón *et al.*, 2022). In our study, we observed a significant correlation between ferritin levels and age, liver function, lipid metabolism, myocardial function, and other biochemical indicators, further suggesting the important role of ferritin in senescence and senescence-associated diseases (Table 2). Therefore, ferritin holds promise as a potential predictive biomarker for senescence-associated diseases.

The ABO blood groups have been associated with a variety of health conditions over the years. A genome-wide association study reported a significant correlation between the ABO locus and ferritin levels (Benyamin *et al.*, 2014). An epidemiological study involving 30,595 participants from the Danish Blood Donor Study indicated that non-O blood group donors exhibited lower ferritin levels compared to those with blood group O (Rigas *et al.*, 2017). However, the interaction between ABO blood groups and ferritin levels during senescence has not been fully elucidated. Our results suggest that the impact of age on ferritin levels varies significantly among different blood groups for the first time, particularly in individuals with blood groups A and B, where the negative correlation between age and ferritin levels is more pronounced (Table 5). The molecular mechanisms underlying the regulatory effect of blood group on ferritin levels in aging remain inadequately understood. However, it has been observed that with advancing age, there is a noted decline in testosterone levels accompanied by an increase in ferritin levels.

This phenomenon contributes to a reduction in iron absorption and utilization (Sudarev *et al.*, 2023), thereby establishing a negative correlation between serum ferritin levels and age as observed in this study. Furthermore, variations in blood groups, attributable to differing capacities for erythropoiesis, result in distinct iron demands, which in turn exert a regulatory influence on serum iron levels (Kronstein-Wiedemann *et al.*, 2023). Based on the above results, we recommended that middle-aged and elderly individuals with blood groups A and B consider iron supplementation.

Strength and limitation

The strength of this study lies in its analysis of the regulatory effect of blood groups on ferritin levels in middle-aged and elderly individuals as a cohesive group. This approach helps to mitigate the loss of continuity associated with ageing that can occur when dividing participants into distinct age groups. Consequently, both the independent and dependent variables in this study are treated as continuous variables.

Our study has several limitations. First, the cross-sectional analysis of the data does not permit a causal assessment of the relationship under investigation. Second, while we have accounted for some confounding factors, our study lacks data on diet and lifestyle, which may influence ferritin levels. Third, although we included and analyzed some relevant biochemical indicators as control variables, the study did not comprehensively cover all biochemical indicators, and the results may be affected by other unmeasured biochemical factors. Therefore, we plan to incorporate questionnaires and follow-up assessments, as well as include additional biochemical indicators, to enhance the comprehensiveness and rigor of the study in the future.

CONCLUSIONS

The ABO blood group appears to influence ferritin levels during ageing, particularly in individuals with blood groups A and B. In these groups, the negative correlation between age and ferritin levels is more pronounced among middle-aged and elderly individuals. The results indicate the possible advantages of administering targeted iron supplementation. Nevertheless, it is essential for future research to investigate the specific dosage-response relationship. The mechanisms by which ABO blood groups affect serum ferritin levels in senescence also require further investigation.

ACKNOWLEDGEMENTS

The authors would like to express their gratitude to all the participants for their voluntary involvement, as well as to the community committee staff for their friendly support.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This work was supported by the National Natural Science Foundation of China (grant number 82301776); State Key Laboratory Special Fund (grant number 2060204); Chinese

Academy of Medical Sciences Innovation Fund for Medical Sciences (grant number 2023-I2M-2-001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:

The National Natural Science Foundation of China: 82301776.

State Key Laboratory Special Fund: 2060204.

Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences: 2023-I2M-2-001.

Competing Interests

The authors declare there are no competing interests.

Author Contributions

- Ni Xiaolin conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.
- Fenghong Yao performed the experiments, prepared figures and/or tables, and approved the final draft.
- Mingkang Pan conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.

Human Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

The Ethics Committee of the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences.

Data Availability

The following information was supplied regarding data availability:

The raw data is available in the [Supplementary File](#).

Supplemental Information

Supplemental information for this article can be found online at <http://dx.doi.org/10.7717/peerj.19281#supplemental-information>.

REFERENCES

Abegaz SB. 2021. Human ABO blood groups and their associations with different diseases. *BioMed Research International* 2021:6629060 DOI [10.1155/2021/6629060](https://doi.org/10.1155/2021/6629060).

Aboelsaad IAF, Claggett BL, Arthur V, Dorbala P, Matsushita K, Lennepe BW, Yu B, Lutsey PL, Ndumele CE, Farag YMK, Shah AM, Buckley LF. 2024. Plasma ferritin levels, incident heart failure, and cardiac structure and function: the ARIC study. *JACC Heart Fail* 12(3):539–548 DOI [10.1016/j.jchf.2023.11.009](https://doi.org/10.1016/j.jchf.2023.11.009).

Anani WQ, Ashwood HE, Schmidt A, Burns RT, Denomme GA, Hoffmeister KM. 2020. Predictive modeling of complex ABO glycan phenotypes by lectin microarrays. *Blood Advances* 4(16):3960–3970 DOI 10.1182/bloodadvances.2020002051.

Benyamin B, Esko T, Ried JS, Radhakrishnan A, Vermeulen SH, Traglia M, Gögele M, Anderson D, Broer L, Podmore C, Luan J, Katalik Z, Sanna S, van der Meer P, Tanaka T, Wang F, Westra HJ, Franke L, Mihailov E, Milani L, Hälldin J, Winkelmann J, Meitinger T, Thiery J, Peters A, Waldenberger M, Rendon A, Jolley J, Sambrook J, Kiemeney LA, Sweep FC, Sala CF, Schwienbacher C, Pichler I, Hui J, Demirkiran A, Isaacs A, Amin N, Steri M, Waeber G, Verweij N, Powell JE, Nyholt DR, Heath AC, Madden PA, Visscher PM, Wright MJ, Montgomery GW, Martin NG, Hernandez D, Bandinelli S, Van der Harst P, Uda M, Vollenweider P, Scott RA, Langenberg C. 2014. Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis. *Nature Communications* 5:4926. Erratum in: *Nat Commun.* 2015 Mar 30;6:6542. DOI: 10.1038/ncomms7542 DOI 10.1038/ncomms5926.

Dieteren CM, Samson LD, Schipper M, Van Exel J, Brouwer WBF, Verschuren WMM, Picavet HSJ. 2020. The healthy aging index analyzed over 15 years in the general population: the Doetinchem cohort study. *Preventive Medicine* 139:106193 DOI 10.1016/j.ypmed.2020.106193.

Fang X, Cai Z, Wang H, Han D, Cheng Q, Zhang P, Gao F, Yu Y, Song Z, Wu Q, An P, Huang S, Pan J, Chen HZ, Chen J, Linkermann A, Min J, Wang F. 2020. Loss of cardiac ferritin H facilitates cardiomyopathy via Slc7a11-mediated ferroptosis. *Circulation Research* 127(4):486–501 DOI 10.1161/CIRCRESAHA.120.316509.

Franchini M, Mengoli C, Capuzzo E, Terenziani I, Bonfanti C, Lippi G. 2016. Correlation between ABO blood group, and conventional hematological and metabolic parameters in blood donors. *Seminars in Thrombosis and Hemostasis* 42(1):75–86 DOI 10.1055/s-0035-1564843.

Goozee K, Chatterjee P, James I, Shen K, Sohrabi HR, Asih PR, Dave P, ManYan C, Taddei K, Ayton SJ, Garg ML, Kwok JB, Bush AI, Chung R, Magnussen JS, Martins RN. 2018. Elevated plasma ferritin in elderly individuals with high neocortical amyloid- β load. *Molecular Psychiatry* 23(8):1807–1812 DOI 10.1038/mp.2017.146.

Hoes MF, Grote Beverborg N, Kijlstra JD, Kuipers J, Swinkels DW, Giepmans BNG, Rodenburg RJ, Van Veldhuisen DJ, De Boer RA, Van der Meer P. 2018. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. *European Journal of Heart Failure* 20(5):910–919 DOI 10.1002/ejhf.1154.

Kronstein-Wiedemann R, Blecher S, Teichert M, Schmidt L, Thiel J, Müller MM, Lausen J, Schäfer R, Tonn T. 2023. Novel evidence that the ABO blood group shapes erythropoiesis and results in higher hematocrit for blood group B carriers. *Leukemia* 37(5):1126–1137 DOI 10.1038/s41375-023-01858-4.

Lawaczeck R. 2020. COVID-19 and body iron: a survey on phenomenological and genetic correlations. *ACS Chemical Neuroscience* 11(24):3996–4000 DOI 10.1021/acschemneuro.0c00572.

Li JY, Feng YH, Li YX, He PY, Zhou QY, Tian YP, Yao RQ, Yao YM. 2024. Ferritinophagy: a novel insight into the double-edged sword in ferritinophagy-ferroptosis axis and human diseases. *Cell Proliferation* 57(7):e13621 DOI [10.1111/cpr.13621](https://doi.org/10.1111/cpr.13621).

Liu Z, Kuo PL, Horvath S, Crimmins E, Ferrucci L, Levine M. 2018. A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: a cohort study. *PLOS Medicine* 15(12):e1002718 DOI [10.1371/journal.pmed.1002718](https://doi.org/10.1371/journal.pmed.1002718).

Maus M, López-Polo V, Mateo L, Lafarga M, Aguilera M, De Lama E, Meyer K, Sola A, Lopez-Martinez C, López-Alonso I, Guasch-Piqueras M, Hernandez-Gonzalez F, Chaib S, Rovira M, Sanchez M, Faner R, Agusti A, Diéguez-Hurtado R, Ortega S, Manonelles A, Engelhardt S, Monteiro F, Stephan-Otto Attolini C, Prats N, Albaiceta G, Cruzado JM, Serrano M. 2023. Iron accumulation drives fibrosis, senescence and the senescence-associated secretory phenotype. *Nature Metabolism* 5(12):2111–2130 DOI [10.1038/s42255-023-00928-2](https://doi.org/10.1038/s42255-023-00928-2).

Philip KEJ, Sadaka AS, Polkey MI, Hopkinson NS, Steptoe A, Fancourt D. 2020. The prevalence and associated mortality of non-anaemic iron deficiency in older adults: a 14 years observational cohort study. *British Journal of Haematology* 189(3):566–572 DOI [10.1111/bjh.16409](https://doi.org/10.1111/bjh.16409).

Rigas AS, Berkfors AA, Pedersen OB, Sørensen E, Nielsen KR, Larsen MH, Paarup HM, Wandall HH, Erikstrup C, Hjalgrim H, Ullum H. 2017. Reduced ferritin levels in individuals with non-O blood group: results from the Danish Blood Donor Study. *Transfusion* 57(12):2914–2919 DOI [10.1111/trf.14364](https://doi.org/10.1111/trf.14364).

Rosell-Díaz M, Santos-González E, Motger-Albertí A, Ramió-Torrentà L, Garre-Olmo J, Pérez-Brocal V, Moya A, Jové M, Pamplona R, Puig J, Ramos R, Fernández-Real JM, Mayneris-Perxachs J. 2023. Gut microbiota links to serum ferritin and cognition. *Gut Microbes* 15(2):2290318 DOI [10.1080/19490976.2023.2290318](https://doi.org/10.1080/19490976.2023.2290318).

Silvestre OM, Gonçalves A, Nadruz Jr W, Claggett B, Couper D, Eckfeldt JH, Pankow JS, Anker SD, Solomon SD. 2017. Ferritin levels and risk of heart failure—the atherosclerosis risk in communities study. *European Journal of Heart Failure* 19:340–347 DOI [10.1002/ejhf.701](https://doi.org/10.1002/ejhf.701).

Suárez-Ortegón MF, McLachlan S, Fernandez-Real JM, Tuomainen TP, Aregbesola A, Wild SH. 2022. Serum ferritin and incident cardiometabolic diseases in Scottish adults. *Cardiovascular Diabetology* 21(1):26 DOI [10.1186/s12933-022-01450-7](https://doi.org/10.1186/s12933-022-01450-7).

Sudarev VV, Dolotova SM, Bukhalovich SM, Bazhenov SV, Ryzhykau YL, Uversky VN, Bondarev NA, Osipov SD, Mikhailov AE, Kuklina DD, Murugova TN, Manukhov IV, Rogachev AV, Gordeliy VI, Gushchin IY, Kuklin AI, Vlasov AV. 2023. Ferritin self-assembly, structure, function, and biotechnological applications. *International Journal of Biological Macromolecules* 224:319–343 DOI [10.1016/j.ijbiomac.2022.10.126](https://doi.org/10.1016/j.ijbiomac.2022.10.126).

Yan J, Guan T, Guo M, Liu J. 2023. Serum ferritin and non-alcoholic fatty liver disease: a meta-analysis and systematic review. *Turkish Journal of Gastroenterology* 34(9):952–960 DOI [10.5152/tjg.2023.22453](https://doi.org/10.5152/tjg.2023.22453).